Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.
Authors
Stijn Hentzen
Kansas University Medical Center, Kansas City, KS
Stijn Hentzen , Kathan Mehta , Raed Moh'd Taiseer Al-Rajabi , Anwaar Saeed , Joaquina Celebre Baranda , Stephen K. Williamson , Weijing Sun , Anup Kasi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.504
Abstract #
504
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2017 ASCO Annual Meeting
68Ga-DOTATATE PET/CT to predict response to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NETs).
First Author: Rohini Sharma
Poster
2016 ASCO Annual Meeting
Circulating neuroendocrine transcripts and gene cluster analysis to predict the efficacy of peptide radioreceptor therapy.
First Author: Lisa Bodei
Poster
2014 Gastrointestinal Cancers Symposium
Effect of dose intensification (DI) of octreotide-LAR (O-LAR) among symptomatic patients with neuroendocrine tumors (NETs).
First Author: Khalid S. Al Efraij